2022. Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 . SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s2. DOI:https://doi.org/10.25251/skin.6.supp.2.